Studies from Weill Cornell Medicine Cornell University Update Current Data on Cholangiocarcinoma [PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in...].

The article focuses on the early termination of the PROOF 301 trial comparing the oral FGFR inhibitor infigratinib to gemcitabine plus cisplatin in treating cholangiocarcinoma. Topics include the preliminary efficacy and safety data of infigratinib, the challenges faced in biomarker-selected studies, and the implications for future confirmatory research in rare tumors.